高迁移率族蛋白 B1 是扩张型心肌病患者全因死亡率的独立预后标志物。

High-Mobility Group Box Protein 1 Is an Independent Prognostic Marker for All-Cause Mortality in Patients With Dilated Cardiomyopathy.

机构信息

Department of Internal Medicine B, Cardiology, University Medicine Greifswald, Greifswald, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Germany.

Department of Internal Medicine B, Cardiology, University Medicine Greifswald, Greifswald, Germany.

出版信息

Am J Cardiol. 2022 Sep 1;178:119-123. doi: 10.1016/j.amjcard.2022.05.014. Epub 2022 Jul 1.

DOI:10.1016/j.amjcard.2022.05.014

PMID:35787339

Abstract

High-mobility group box protein 1 (HMGB1) is released during tissue damage and activates the innate immune system through toll-like receptor 4. Because mortality in dilated cardiomyopathy (DCM) is associated with activation of the innate immune system, we hypothesized that HMGB1 possesses a prognostic value in estimating mortality in patients with DCM. We determined HMGB1 and N-terminal B-type natriuretic peptide (NT-proBNP) levels in 67 patients with DCM (12 women, mean age 53.6 ± 1.5 years). Kaplan-Meier analyzes revealed that higher levels of HMGB1 and NT-proBNP are related to increased all-cause mortality. Multivariable Cox regression confirmed HMGB1 as a risk factor for mortality in patients with DCM, independent of NT-proBNP, age, and gender (hazard ratio per 1 SD 1.920, 95% confidence interval 1.401 to 2.631, p <0.001). HMGB1 is a promising candidate to estimate the prognosis of patients with DCM.

摘要

高迁移率族蛋白 B1（HMGB1）在组织损伤时释放，并通过 toll 样受体 4 激活先天免疫系统。由于扩张型心肌病（DCM）患者的死亡率与先天免疫系统的激活有关，我们假设 HMGB1 在估计 DCM 患者死亡率方面具有预后价值。我们测定了 67 例 DCM 患者（12 例女性，平均年龄 53.6±1.5 岁）的 HMGB1 和 N 末端 B 型利钠肽（NT-proBNP）水平。Kaplan-Meier 分析显示，HMGB1 和 NT-proBNP 水平较高与全因死亡率增加相关。多变量 Cox 回归证实，HMGB1 是 DCM 患者死亡的危险因素，独立于 NT-proBNP、年龄和性别（每 1 SD 的危险比为 1.920，95%置信区间为 1.401 至 2.631，p＜0.001）。HMGB1 是估计 DCM 患者预后的有前途的候选物。